Joshua Nahm

ORCID: 0000-0002-1466-4188
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Ocular Oncology and Treatments
  • Alzheimer's disease research and treatments
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Boron Compounds in Chemistry
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Genomics and Diagnostics
  • Hedgehog Signaling Pathway Studies
  • Neurosurgical Procedures and Complications
  • Spinal Hematomas and Complications
  • Tryptophan and brain disorders
  • Lung Cancer Treatments and Mutations
  • Head and Neck Surgical Oncology
  • CNS Lymphoma Diagnosis and Treatment
  • Ubiquitin and proteasome pathways

The University of Texas Health Science Center at Houston
2023-2024

Alzheimer's disease (AD) is characterized by the presence of two hallmark pathologies: accumulation Amyloid beta (Aβ) and tau proteins in brain. There a growing body evidence suggesting that astrocytes, type glial cell brain, play crucial roles clearing Aβ binding to proteins. However, due heterogeneity specific different astrocyte subpopulations response remain unclear. To enhance understanding AD, we investigated lineage cells based on single-nuclei transcriptomic data obtained from both...

10.14336/ad.2024.0205-1 article EN cc-by Aging and Disease 2024-01-01

To report two high-grade glioma (HGG) cases with extracranial metastases (EXM) pathological review and next-generation sequencing (NGS) data.

10.1212/wnl.0000000000206490 article EN Neurology 2024-04-09

e14057 Background: Glioblastoma (GBM) is the most common malignant primary brain tumor with an annual incidence of 3.19 per 100,000 and a very poor prognosis. The median overall survival (OS) 14.6 to 23 months for clinical trial participants 11 real-world population. Most GBM recurs in 6 9 OS since recurrence 3 months. Despite advancements trials, there no uniform standard care (SOC) recurrent GBM. We investigated combination therapy TTF temozolomide, bevacizumab, irinotecan (TBI)...

10.1200/jco.2023.41.16_suppl.e14057 article EN Journal of Clinical Oncology 2023-06-01

<h3>Objective:</h3> LP is one of the most frequently used diagnostic modalities in neurology and neurosurgery. Post-LP headache (PLPH) common complication (10–32%). Epidural blood patch a treatment to cure severe prolonged PLPH. <h3>Background:</h3> PLPH associated with cerebrospinal fluid (CSF) leakage after LP. Usually, patients exhibit headaches upright body positions. Various prophylactic therapeutic treatments have been reduce treat including keeping supine position for four hours...

10.1212/wnl.0000000000203808 article EN Neurology 2023-04-25

Abstract Choroid plexus carcinoma (CPC) is a malignant primary brain tumor that extremely rare in adults. Previous literature has reported median overall survival of 2.7 years among pediatric and adult cases. However, data regarding CPC's genomic profile by next-generation sequencing (NGS), pathogenesis, adjuvant treatments after maximum safe resection radiotherapy remains limited. CASE DESCRIPTION: A 53-year-old female was diagnosed with CPC found PTEN PREX2 mutations NGS. She underwent...

10.1093/noajnl/vdad071.027 article EN cc-by-nc-nd Neuro-Oncology Advances 2023-07-01

Abstract Anaplastic pleomorphic xanthoastrocytomas (aPXA) are rare gliomas with a five-year survival of 57%. Standard treatment involves maximal safe resection followed by radiotherapy. BRAF mutation is frequently seen in these patients and promising target concurrent MEK inhibitors. However, there no standard for aPXA leptomeningeal disease (LMD). Literature review identified four cases overall survivals (OS) 3, 4, 18, 66 months, respectively. We report 23-year-old female who presented...

10.1093/neuonc/noad179.0015 article EN Neuro-Oncology 2023-11-01
Coming Soon ...